Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090486 · ClinicalTrials.gov registry record
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 14,000
- Enrollment target
NCT07090486 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 14,000 participants.
The verdict
NCT07090486 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 14,000 participants
- Enrollment target
Study Summary
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency department, urgent care and inpatient visits before and after COVID-19 between those who did and did not receive Paxlovid. In addition, changes in frailty post-acute infection will be evaluated, in a separate analysis. It is hypothesized that individuals with COVID-19 who received Paxlovid will have a smaller post-COVID-19 increase (vs pre-COVID) in PCC healthcare utilization (i.e., cardiopulmonary) in comparison to patients with COVID-19 who did not receive Paxlovid.
Interventions
- DRUG nirmatrelvir-ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,000 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2025-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07090486
The ClinicalTrials.gov registry entry for NCT07090486 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nirmatrelvir-ritonavir is the first listed.
NCT07090486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07090486 about?
NCT07090486 is a clinical study titled "A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.". This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom. This study will look at the change in Post Covid Conditions measured by the number of outpatients, Emergency departme...
What is the current status of trial NCT07090486?
This trial is currently completed. The enrollment target is 14,000 participants. The study started on 2025-04-15. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT07090486?
The interventions under investigation include: nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07090486?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.